FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103927033> ?p ?o ?g. }

• W2103927033 endingPage "1570" @default.
• W2103927033 startingPage "1558" @default.
• W2103927033 abstract "Background: EphA2 is an oncoprotein and tyrosine kinase receptor that is overexpressed in ovarian and many other cancers. We investigated the effects of reduced EphA2 levels on tumor growth and the tumor microenvironment in an orthotopic ovarian cancer model. Methods: The effect of the EphA2-agonistic monoclonal antibody EA5, alone or in combination with paclitaxel, on the growth of ovarian cancer cells (SKOV3ip1, HeyA8, and HeyA8MDR [taxane–platinum resistant]) was determined in vitro and in vivo by immunoblotting, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay, and immunohistochemical analysis. Expression of EphA2 and markers of angiogenesis (CD31, vascular endothelial growth factor [VEGF], and basic fibroblast growth factor), proliferation (proliferating cell nuclear antigen), and endothelial cell apoptosis (CD31–terminal deoxynucleotidyl transferase biotin–deoxyuridine triphosphate nick-end labeling colocalization) and phosphorylation of Src were analyzed by immunoblotting, immunohistochemistry, immunofluorescence, and in situ hybridization in tumors from treated mice. Statistical tests were two-sided. Results: EA5 antibody treatment led to a more than 90% reduction in EphA2 expression in HeyA8 tumors in vivo. In mice bearing orthotopic SKOV3ip1 or HeyA8 tumors, 4 weeks of EA5 treatment resulted in tumors that weighed 31% and 45% less, respectively, than those in control (IgG-treated) mice (95% confidence interval [CI] = −0.09% to 71% and 20% to 70%, P = .27 and .01, respectively). Combination therapy with EA5 and paclitaxel reduced tumor weight by 77% and 80% (95% CI = 63% to 91% and 68% to 91%), respectively, compared with paclitaxel alone and by 92% and 88% (95% CI = 87% to 97% and 80% to 94%), respectively, compared with IgG alone. Combination therapy also reduced the weight of HeyA8MDR tumors by 47% (95% CI = 24% to 72%) compared with paclitaxel. Mice bearing SKOV3ip1 or HeyA8 tumors that were treated with combination therapy survived longer than those treated with paclitaxel alone (median survival = 144 versus 69 days and 46 versus 37 days, respectively). EA5-treated tumors had reduced microvascular density, proliferation, and VEGF protein and mRNA levels, with increased endothelial cell apoptosis. EphA2 was associated with Src, which was rapidly dephosphorylated after EA5 treatment. Conclusions: EA5 in combination with paclitaxel decreased tumor growth in an orthotopic ovarian cancer mouse model through antiangiogenic mechanisms associated with reduced levels of VEGF and phosphorylated Src. Humanized antibody constructs against EphA2 are worthy of future study." @default.
• W2103927033 created "2016-06-24" @default.
• W2103927033 creator A5004439513 @default.
• W2103927033 creator A5009442045 @default.
• W2103927033 creator A5011112601 @default.
• W2103927033 creator A5018891733 @default.
• W2103927033 creator A5019407817 @default.
• W2103927033 creator A5024497385 @default.
• W2103927033 creator A5038143218 @default.
• W2103927033 creator A5039017321 @default.
• W2103927033 creator A5042760638 @default.
• W2103927033 creator A5043286309 @default.
• W2103927033 creator A5046763527 @default.
• W2103927033 creator A5048503523 @default.
• W2103927033 creator A5052134778 @default.
• W2103927033 creator A5052946108 @default.
• W2103927033 creator A5057441533 @default.
• W2103927033 creator A5064842058 @default.
• W2103927033 creator A5067465729 @default.
• W2103927033 creator A5067490446 @default.
• W2103927033 creator A5072844231 @default.
• W2103927033 date "2006-11-01" @default.
• W2103927033 modified "2023-10-17" @default.
• W2103927033 title "Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer" @default.
• W2103927033 cites W1512634984 @default.
• W2103927033 cites W1539571840 @default.
• W2103927033 cites W1835347798 @default.
• W2103927033 cites W1963592300 @default.
• W2103927033 cites W1965680643 @default.
• W2103927033 cites W1967628309 @default.
• W2103927033 cites W1967720639 @default.
• W2103927033 cites W1972035895 @default.
• W2103927033 cites W1978165300 @default.
• W2103927033 cites W1982317652 @default.
• W2103927033 cites W1985903403 @default.
• W2103927033 cites W1992642151 @default.
• W2103927033 cites W1994137567 @default.
• W2103927033 cites W1999796822 @default.
• W2103927033 cites W2006573558 @default.
• W2103927033 cites W2007194438 @default.
• W2103927033 cites W2011907603 @default.
• W2103927033 cites W2013594457 @default.
• W2103927033 cites W2015146505 @default.
• W2103927033 cites W2017923612 @default.
• W2103927033 cites W2020050363 @default.
• W2103927033 cites W2030537346 @default.
• W2103927033 cites W2034073392 @default.
• W2103927033 cites W2034538527 @default.
• W2103927033 cites W2038894508 @default.
• W2103927033 cites W2040291225 @default.
• W2103927033 cites W2049547244 @default.
• W2103927033 cites W2051337269 @default.
• W2103927033 cites W2063757122 @default.
• W2103927033 cites W2064127450 @default.
• W2103927033 cites W2066300288 @default.
• W2103927033 cites W2071946945 @default.
• W2103927033 cites W2076424556 @default.
• W2103927033 cites W2079537409 @default.
• W2103927033 cites W2085761836 @default.
• W2103927033 cites W2094161067 @default.
• W2103927033 cites W2108613636 @default.
• W2103927033 cites W2112310634 @default.
• W2103927033 cites W2115472066 @default.
• W2103927033 cites W2129825215 @default.
• W2103927033 cites W2136929338 @default.
• W2103927033 cites W2145807414 @default.
• W2103927033 cites W2147846166 @default.
• W2103927033 cites W2157114107 @default.
• W2103927033 cites W2157769714 @default.
• W2103927033 cites W2158158704 @default.
• W2103927033 cites W2163727727 @default.
• W2103927033 cites W2170726369 @default.
• W2103927033 cites W2179038141 @default.
• W2103927033 cites W2327287238 @default.
• W2103927033 cites W2410771478 @default.
• W2103927033 cites W4230112911 @default.
• W2103927033 cites W4296791294 @default.
• W2103927033 doi "https://doi.org/10.1093/jnci/djj414" @default.
• W2103927033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17077358" @default.
• W2103927033 hasPublicationYear "2006" @default.
• W2103927033 type Work @default.
• W2103927033 sameAs 2103927033 @default.
• W2103927033 citedByCount "117" @default.
• W2103927033 countsByYear W21039270332012 @default.
• W2103927033 countsByYear W21039270332013 @default.
• W2103927033 countsByYear W21039270332014 @default.
• W2103927033 countsByYear W21039270332015 @default.
• W2103927033 countsByYear W21039270332016 @default.
• W2103927033 countsByYear W21039270332017 @default.
• W2103927033 countsByYear W21039270332018 @default.
• W2103927033 countsByYear W21039270332019 @default.
• W2103927033 countsByYear W21039270332020 @default.
• W2103927033 countsByYear W21039270332021 @default.
• W2103927033 countsByYear W21039270332022 @default.
• W2103927033 crossrefType "journal-article" @default.
• W2103927033 hasAuthorship W2103927033A5004439513 @default.
• W2103927033 hasAuthorship W2103927033A5009442045 @default.
• W2103927033 hasAuthorship W2103927033A5011112601 @default.

• next